Author’s response to reviews

Title: Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: A meta-analysis based on the PRISMA statement

Authors:

Danjuan Li (miamili@foxmail.com)
Dong Xiao (xiao_d@hotmail.com)

Version: 5 Date: 08 Jul 2017

Author’s response to reviews:

Dear Editors,

Thank you very much for your letter and for the comments concerning our manuscript entitled “Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: A meta-analysis based on the PRISMA statement” (ID: BCAN-D-16-01768R4). We have made correction according to the comments which we hope meet with approval. The main corrections in the paper and the responds to the comments are as following:

Editor Comments:

1. Thank you for providing your 'Availability of data and materials' section. However, please provide weblinks to the datasets on each repository (PubMed, CNKI, EBSCO and Cochrane).

Answer: Weblinks of each study included in the datasets have been provided in the “Reference” part.

2. Please rename 'Materials and methods' to 'Methods'.

Answer: 'Materials and methods' has been renamed as 'Methods'.

3. Please remove the 'Acknowledgements' section on page 12 as this is duplicated in the 'Declarations' section.
4. I'm afraid the quality of the English used throughout your manuscript does not currently meet our requirements and requires a minor copy-edit. We recommend that you ask a native English speaking colleague to help you copyedit the paper. If this is not possible, you may need to use a professional language editing service. Use of an editing service is neither a requirement nor a guarantee of acceptance for publication.

Answer: Minor modification has made to the manuscript to make it more fluent. We hope it can meet the requirements.